BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 07, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the Company is presenting evidence of strong immune system engagement and anti-cancer activity of its next generation Bria-OTS+ platform in preclinical models at a poster presentation at the Society for Immunotherapy of Cancer (SITC) 40^th Anniversary Annual Meeting, to be held November 7-9, 2025, in National Harbor, MD.

Read more at globenewswire.com